<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "capecitabine tab">
<dose><value>1250</value>
<value>1000</value>
<value>500</value>
<value>650</value>
<value>800</value>
<value>950</value>
<value>1150</value>
<value>1300</value>
<value>1450</value>
<value>1500</value>
<value>1650</value>
<value>1800</value>
<value>1950</value>
<value>2000</value>
<value>2150</value>
<value>2300</value>
<value>2450</value>
<value>2500</value>
<value>2650</value>
<value>2800</value>
<value>2950</value>
<value>3000</value>
<value>3150</value>
</dose><route><value>PO</value>
</route><form><value>tab</value>
</form><drugname><value>capecitabine tab</value>
</drugname><strength><value>150 mg</value>
<value>500 mg</value>
</strength><frequency><value>BID</value>
</frequency><instruction><value>Administer in the morning and evening.</value>
<value>Start treatment during the evening of Day 1 and last dose during morning of Day 15. Administer in the morning and evening.</value>
</instruction><volume></volume><units><value>mg/m2</value>
<value>mg</value>
</units><additionalnotes><value>Monotherapy. Treatment cycle of 14 days of treatment followed by 7 day rest period. If ANC is greater than or equal to 1.5 X 109/L AND Platelets are greater than or equal to 75 X 109/L: Give as ordered. If ANC is less than 1.5 X109/L OR Platelets are less than 75 X 109/L: Delay 1 week. Dosage adjust for renal impairment (Cycle #1 ONLY): If CrCl is greater than 50 mL/minute: NO dosage adjustment. If CrCl is 30 to 50 mL/minute: Reduce dose to 75%. If CrCl is less than 30 mL/minute: DO NOT TREAT. Recommend rounding dose to a "dispensable" dose amount.</value>
<value>Combination therapy. Treatment cycle of 14 days of treatment followed by 7 day rest period. If ANC is greater than or equal to 1.5 X 109/L AND Platelets are greater than or equal to 75 X 109/L: Give as ordered. If ANC is less than 1.5 X109/L OR Platelets are less than 75 X 109/L: Delay 1 week. Dosage adjust for renal impairment (Cycle #1 ONLY): If CrCl is greater than 50 mL/minute: NO dosage adjustment. If CrCl is 30 to 50 mL/minute: Reduce dose to 75%. If CrCl is less than 30 mL/minute: DO NOT TREAT. Recommend rounding dose to a "dispensable" dose amount.</value>
<value>Monotherapy. Treatment cycle of 14 days of treatment followed by 7 day rest period.</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3351</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3352</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose></maximumprndose><din><value>02238453</value>
<value>02238454</value>
</din><type><value>Medication/IV Therapy</value>
</type></drug>